References
- ScaglioneFCan PK/PD be used in everyday clinical practiceInt J Antimicrob Agents20021934935311978506
- CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis1998261109455502
- WilsonAPGrünebergRNNeuHA critical review of the dosage of teicoplanin in Europe and the USAInt J Antimicrob Agents19944Suppl 113018611626
- KutiJLKifferCRMendesCMNicolauDPPharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in BrazilClin Microbiol Infect20081411612318076672
- CraigWABasic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolidInfect Dis Clin North Am20031747950114711073
- MatsumotoKTakesueYOhmagariNPractice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug MonitoringJ Infect Chemother20131936538023673472
- RybakMLomaestroBRotschaferJCTherapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAm J Health Syst Pharm200966829819106348
- CockcroftDWGaultMHPrediction of creatinine clearance from serum creatinineNephron19761631411244564
- NakayamaKGemmaHKaibaraANiwaTPopulation pharmacokinetics of teicoplanin in adult patientsJpn J Chemother20065416
- WiklerMAHindlerJFCockerillFRMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard8th edClinical and Laboratory Standards InstituteWayne, PA, USA2009 Document M7-A8
- MatsumotoKKanazawaNIkawaKDetermination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infectionsJ Infect Chemother20101619319920195882
- HagiharaMUmemuraTKimuraMMoriTHasegawaTMikamoHExploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureusJ Infect Chemother201218101621710160
- KanazawaNMatsumotoKIkawaKAn initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradicationJ Infect Chemother20111729730020714913
- OgawaRKobayashiSSasakiYMakimuraMEchizenHPopulation pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infectionInt J Clin Pharmacol Ther20135135736623458228
- TamVHMcKinnonPSAkinsRLRybakMJDrusanoGLPharmacodynamics of cefepime in patients with Gram-negative infectionsJ Antimicrob Chemother20025042542812205070